You are seeing these quotes based on previous browsing related to sectors such as
Latest | Forecast | |
---|---|---|
Div Yield | 0.0% | 0.0% |
Div Cover | n/a | n/a |
Op Mrgn | -265.4% | -250.4% |
ROCE | 0.0% |
Latest | Forecast | |
---|---|---|
P/E | -1.5 | 0.0 |
PEG | 0.0 | -999,999.0 |
Price / Revenue | 4.1 | 2.3 |
Price / Book value | 0.5 |
Latest | Forecast | |
---|---|---|
Revenue | -30.8% | 0.0% |
PBT | 0.0% | n/a |
EPS | 0.0% | 0.0% |
DPS | n/a | 0.0% |
Year Ending | Revenue (£m) |
Pre-tax (£m) |
EPS | P/E | PEG | EPS Growth | Div | Yield |
---|---|---|---|---|---|---|---|---|
2018-06-30 | 0.07 | -16.91 | -26.52p | -7.0 | 0.0 | n/a | n/a | 0.0% |
2019-06-30 | 1.04 | -14.40 | -19.68p | -1.6 | 0.0 | n/a | n/a | 0.0% |
2020-06-30 | 6.31 | -5.28 | -4.30p | -7.2 | 0.0 | n/a | n/a | 0.0% |
2021-06-30 | 4.37 | -11.54 | -7.30p | -8.8 | 0.0 | n/a | n/a | 0.0% |
Director dealings: K3 director linked to purchase, Diurnal exec sells shares into ISA Sharecast News | 09 May |
---|---|
Diurnal inks distribution agreement with Vector Pharma Sharecast News | 30 Mar |
Diurnal agrees special protocol with FDA for Chronocort study Sharecast News | 12 Jul |
Block Listing Six Monthly Return | 30-Jun-22 13:33 |
---|---|
Diurnal to present research at ENDO 2022 | 07-Jun-22 13:02 |
First patient dosed in pivotal Phase 3 trial | 01-Jun-22 07:00 |
Correction: Presentation at ECE | 23-May-22 08:42 |
Presentation at European Congress of Endocrinology | 23-May-22 07:00 |